Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:29 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Belatacept for Renal Transplant Recipients With Delayed Graft Function
NCT02134288 · Ohio State University · EARLY_PHASE1 · terminated · last registry update 2021-09-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Drug unavailability due to a manufacturing transition.” | – | Registry record, Ohio State University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD86 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-08-29Results posted on the registry: George Washington University, Abatacept (NCT02594735)
- 2022-08-25Phase 3 first posted: Federal Research Institute of Pediatric Hematology, Oncology and Immunology, GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor (NCT05515029)
- 2022-07-11Phase 3 first posted: Zhejiang Provincial People's Hospital, Janus Kinase Inhibitor + Abatacept (NCT05451615)
- 2022-06-23Phase 3 first posted: University Hospital, Montpellier, Abatacept (W12-W48) + TNF Inhibitor (W12-W48) (NCT05428488)
- 2022-04-20Phase 3 first posted: Massachusetts General Hospital, Abatacept plus + Placebo (NCT05335928)
- 2021-11-29Also stopped (terminated): Stuart Knechtle, M.D., Orencia® (Abatacept) (NCT04203875)
- 2021-11-02Results posted on the registry: Washington University School of Medicine, Belatacept + Tacrolimus (NCT03388008)
- 2021-09-17Results posted on the registry: Bristol-Myers Squibb, Abatacept subcutaneous + Placebo (NCT02971683)
- 2021-09-08Results posted on the registry: Lorenzo Gallon, belatacept + Tacrolimus (NCT02213068)
- 2021-09-02Results posted on the registry: Massachusetts General Hospital, Belatacept + ATG (NCT02314403)
- 2021-08-24Results posted on the registry: Massachusetts General Hospital, Abatacept (NCT03669861)
- 2021-07-28Results posted on the registry: University of Cincinnati, Alemtuzumab + rabbit antithymocyte globulin (NCT01729494)
- 2021-06-22Results posted on the registry: Bristol-Myers Squibb, Thymoglobulin + Belatacept (NCT02137239)
- 2021-06-02Phase 3 first posted: Bristol-Myers Squibb, Abatacept + Adalimumab (NCT04909801)
- 2021-05-13Results posted on the registry: University of California, Los Angeles, abatacept also known as Orencia also known as CTLA4-Ig + Placebo (NCT02429934)
- 2021-05-13Also stopped (terminated): University of California, Los Angeles, abatacept also known as Orencia also known as CTLA4-Ig + Placebo (NCT02429934)
- 2021-05-07Phase 3 first posted: Bristol-Myers Squibb, Belatacept + Tacrolimus (NCT04877288)
- 2021-03-05Results posted on the registry: Bristol-Myers Squibb, Abatacept (NCT02592798)
- 2021-02-26Also stopped (terminated): Bristol-Myers Squibb, BMS-188667 + Mycophenolate mofetil (NCT01714817)
- 2021-01-26Results posted on the registry: Andrew B Adams, Belatacept + Calcineurin inhibitor therapy (NCT01921218)
- 2021-01-07Results posted on the registry: Bristol-Myers Squibb, Abatacept (NCT03714022)
- 2021-01-05Results posted on the registry: Bristol-Myers Squibb, Belatacept + Tacrolimus (NCT01820572)
- 2020-12-31Phase 3 first posted: University of Alabama at Birmingham, targeted synthetic DMARD class + non-TNFi-biologic class (NCT04692493)
- 2020-12-01Also stopped (terminated): Medical University of Graz, bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept) (NCT01602302)
- 2020-11-25Results posted on the registry: Oklahoma Medical Research Foundation, Abatacept (NCT02270957)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision